Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

2 results

  • A short historical review of SCNP with special reference to the UKU

  • Per Bech, Thomas A. Ban
  • Journal:
    Acta Neuropsychiatrica / Volume 26 / Issue 1 / February 2014
    Published online by Cambridge University Press:
    14 October 2013, pp. 4-7
  • Objective

    To give a review of the history of SCNP since the first meeting in 1960 with specific focus on UKU.

    Methods

    Consulting the appropriate minutes from the meetings.

    Results

    One of the major goals of the SCNP was the standardization of clinical trials with psychotropic drugs. In 1969, the SCNP established a Committee for Clinical Investigations (UKU) with the representation of clinical investigators and the drug industry; moreover, during the 1970s and ’80s, the UKU initiated clinical trialsand contributed to the methodology of clinical investigations with psychotropic drugs. With the decrease in governmental funding and increasing influence of the US Food and Drug Administration on themethodology of clinical investigations around the world in the 1990s, the UKU was dissolved. The changes had a detrimental effect on the developments on the methodology of clinical investigations, and the lack of clinical feedback led to an impasse in psychotropic drug development with some pharmaceutical companies abandoning research in the central nervous system area.

    Conclusion

    It is suggested that a revival of UKU to provide a platform for dialogue among government, industry, and academia could help break the impasse.

  • 20 - Pharmacogenetics in psychotropic drug discovery and development

  • from Part VII - Industry perspectives
  • Edited by Bernard Lerer, Hadassah-Hebrew Medical Center, Jerusalem
  • Book:
    Pharmacogenetics of Psychotropic Drugs
    Published online:
    20 August 2009
    Print publication:
    29 August 2002, pp 403-421

  • Summary

    Drug development for the central nervous system (CNS) emphasizes whole-genome single nucleotide polymorphism (SNP) disequilibrium mapping of patients in phase II trials followed by a more focused abbreviated SNP linkage disequilibrium mapping in phase III trials, as proposed by Roses. This chapter discusses why this is not the general case and emphasizes the need for success stories to allow those involved in leading CNS drug development to obtain the necessary support for a sustainable effort in pharmacogenetics. Determination of the association between genotype and phenotype requires an a priori hypothesis that a particular candidate allele is responsible for expression of the phenotype. Genetic studies can help to identify molecular targets and thereby accelerate drug discovery. Despite the concerns about the value of genetic research in the pharmaceutical industry, pharmacogenetics and pharmacogenomics will be a foundation for modern drug development.